Preclinical Evaluation of Recombinant Microbial Glycoside Hydrolases in the Prevention of Experimental Invasive Aspergillosis-Reference-Cited by-同舟云学术

Preclinical Evaluation of Recombinant Microbial Glycoside Hydrolases in the Prevention of Experimental Invasive Aspergillosis

Published:2021-10-26 Issue:5 Volume:12 Page:
ISSN:2150-7511
Container-title:mBio
language:en
Short-container-title:mBio

Author:

Ostapska Hanna¹²³,Raju Deepa⁴,Lehoux Melanie¹²³,Lacdao Ira²³⁴,Gilbert Stephanie⁴,Sivarajah Piyanka⁴,Bamford Natalie C.⁴⁵,Baker Perrin⁴,Nguyen Thi Tuyet Mai²³,Zacharias Caitlin A.¹²³,Gravelat Fabrice N.¹²³,Howell P. Lynne⁴⁵^ORCID,Sheppard Donald C.¹²³⁶

Affiliation:

1. Department of Microbiology and Immunology, McGill University, Montreal, Canada

2. Infectious Disease and Immunity in Global Health Program, McGill University Health Centre, Montreal, Canada

3. McGill Interdisciplinary Initiative in Infection and Immunity, Montreal, Canada

4. Program in Molecular Medicine, Research Institute, The Hospital for Sick Children, Toronto, Canada

5. Department of Biochemistry, University of Toronto, Toronto, Canada

6. Department of Medicine, McGill University, Montreal, Canada

Abstract

The biofilm-forming mold Aspergillus fumigatus is a common causative agent of invasive fungal airway disease in patients with a compromised immune system or chronic airway disease. Treatment of A. fumigatus infection is limited by the few available antifungals to which fungal resistance is becoming increasingly common.

Funder

DOD | U.S. Army

Cystic Fibrosis Canada

U of A | Canadian Glycomics Network

Publisher

American Society for Microbiology

Subject

Virology,Microbiology

Link

https://journals.asm.org/doi/pdf/10.1128/mBio.02446-21

Reference39 articles.

1. Hidden Killers: Human Fungal Infections